Becton, Dickinson and Co ((BDX)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: The study titled A Comparative Crossover Study on the Safety, Efficacy, and Patient Reported Satisfaction of the PureWick™ System With an Established Comparator Overnight in the Home Setting for Incontinence in Adult Males aims to evaluate the performance and user satisfaction of the PureWick™ Male External Catheter. Conducted by C. R. Bard with collaboration from Becton, Dickinson and Company, this study is significant for improving overnight urine management solutions for adult males.
Intervention/Treatment: The study tests two devices: the PureWick™ System and the UltraFlex™ Self-Adhering Male External Catheter. Both are designed for non-invasive urine output management in males, with the PureWick™ System being a commercially available, single-use device.
Study Design: This interventional study uses a randomized, crossover model without masking. Participants are divided into two groups, each using both devices in different sequences to assess efficacy and safety, focusing on supportive care.
Study Timeline: The study began on March 21, 2025, with its primary completion and last update submitted on June 27, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data collection.
Market Implications: The completion of this study could influence Becton, Dickinson and Co’s stock performance by potentially increasing market share in the male incontinence management sector. Positive results may enhance investor confidence, especially in comparison to competitors offering similar solutions.
The study has been completed, with further details available on the ClinicalTrials portal.